Concepedia

Jens Nagel

JN

25

Publications

938

Citations

19

H-Index

1998

Active since

Affiliations

MerLion Pharma (Germany)(Current)

Bayer (Germany)

University of Stuttgart

University of Oxford

Heidelberg University

Jens Nagel is an author at MerLion Pharma (Germany) specializing in medicine, pharmacology, and neuropharmacology.

ORCID

Top concepts

Publications per year

1998–2023

25

Publications

25

Catalepsy induced by a blockade of dopamine D<sub>1</sub> or D<sub>2</sub> receptors was reversed by a concomitant blockade of adenosine A<sub>2A</sub> receptors in the caudate‐putamen of rats

Wolfgang Hauber, Patric Neuscheler, Jens Nagel et al. · European Journal of Neuroscience · 2001 · 109 citations

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition

Chantal Schlumberger, D. Schäfer, Caroline Barberi et al. · Behavioural Pharmacology · 2009 · 71 citations

, , +19

Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen

Wolfgang Hauber, Jens Nagel, R. Sauer et al. · Neuroreport · 1998 · 65 citations

The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning

W. Jacob, Andreas Gravius, M. Pietraszek et al. · Neuropharmacology · 2009 · 63 citations

, , +12

Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour

Nico Wegener, Jens Nagel, Ralph Gross et al. · Neuroscience Letters · 2011 · 60 citations

, , +10

Rows per page

1–5 of 25